Since the passage of the Biologics Price Competition and Innovation Act (BPCIA), the field of biosimilars has expanded and evolved. Keeping abreast of these changes helps stakeholders.
Nearly 40 years ago, Congress signed into law the Hatch-Waxman Act, balancing the need for lower cost prescription drugs and the protection of pharmaceutical innovations. For both.